{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:20:49Z","timestamp":1789129249023,"version":"build-2803163510"},"reference-count":123,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.clml.2024.08.005","type":"journal-article","created":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T01:52:44Z","timestamp":1723254764000},"page":"13-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["SOHO State of the Art Updates and Next Questions | Approach to BCR::ABL1-Like Acute Lymphoblastic Leukemia"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2008-1365","authenticated-orcid":false,"given":"Ilaria","family":"Iacobucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8705-8333","authenticated-orcid":false,"given":"Cristina","family":"Papayannidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.08.005_bib0001","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1182\/blood-2004-12-4938","article-title":"Global approach to the diagnosis of leukemia using gene expression profiling","volume":"106","author":"Haferlach","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.005_bib0002","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","article-title":"A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study","volume":"10","author":"Den Boer","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.08.005_bib0003","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.08.005_bib0004","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","article-title":"Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia","volume":"22","author":"Roberts","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2024.08.005_bib0005","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.08.005_bib0006","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ccell.2015.12.013","article-title":"Truncating erythropoietin receptor rearrangements in acute lymphoblastic leukemia","volume":"29","author":"Iacobucci","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2024.08.005_bib0007","first-page":"1657","article-title":"Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL","volume":"1","author":"Roberts","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2024.08.005_bib0008","doi-asserted-by":"crossref","DOI":"10.3390\/genes12050687","article-title":"Genetic alterations and therapeutic targeting of Philadelphia-like acute lymphoblastic leukemia","volume":"12","author":"Iacobucci","year":"2021","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.clml.2024.08.005_bib0009","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.005_bib0010","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.005_bib0011","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.08.005_bib0012","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2016-07-726588","article-title":"Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults","volume":"129","author":"Jain","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.005_bib0013","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/ng.2803","article-title":"Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse","volume":"45","author":"Perez-Andreu","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2024.08.005_bib0014","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23179587","article-title":"Characterization of Philadelphia-like Pre-B acute lymphoblastic leukemia: experiences in Mexican pediatric patients","volume":"23","author":"Martinez-Anaya","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clml.2024.08.005_bib0015","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/blood-2016-12-758979","article-title":"Targetable kinase gene fusions in high-risk B-ALL: a study from the children's oncology group","volume":"129","author":"Reshmi","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.005_bib0016","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2016.69.0073","article-title":"High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults","volume":"35","author":"Roberts","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.08.005_bib0017","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/leu.2016.375","article-title":"High incidence of Philadelphia chromosome-like acute lymphoblastic leukemia in older adults with B-ALL","volume":"31","author":"Tasian","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.08.005_bib0018","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.3324\/haematol.2014.117424","article-title":"Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates","volume":"100","author":"Boer","year":"2015","journal-title":"Haematol"},{"key":"10.1016\/j.clml.2024.08.005_bib0019","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/s41588-022-01159-z","article-title":"The genomic landscape of pediatric acute lymphoblastic leukemia","volume":"54","author":"Brady","year":"2022","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2024.08.005_bib0020","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1182\/hematology.2022000357","article-title":"Clinical screening for Ph-like ALL and the developing role of TKIs","volume":"2022","author":"Tran","year":"2022","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2024.08.005_bib0021","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood-2018-04-841676","article-title":"Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the children's oncology group","volume":"132","author":"Roberts","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.005_bib0022","doi-asserted-by":"crossref","first-page":"E11711","DOI":"10.1073\/pnas.1814397115","article-title":"Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases","volume":"115","author":"Li","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.clml.2024.08.005_bib0023","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1182\/bloodadvances.2021006076","article-title":"SFPQ-ABL1 and BCR-ABL1 use different signaling networks to drive B-cell acute lymphoblastic leukemia","volume":"6","author":"Brown","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2024.08.005_bib0024","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/10428194.2023.2264428","article-title":"Sustained long-term remission with tyrosine kinase inhibitor therapy in treatment-refractory B-cell acute lymphoblastic leukemia harboring a RCSD1::ABL2 fusion gene","volume":"65","author":"Zahid","year":"2024","journal-title":"Leuk Lym"},{"key":"10.1016\/j.clml.2024.08.005_bib0025","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1097\/HS9.0000000000000193","article-title":"Efficacy of tyrosine kinase inhibitor therapy in a chemotherapy-refractory B-cell precursor acute lymphoblastic leukemia with ZC3HAV1-ABL2 fusion","volume":"3","author":"Decool","year":"2019","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2024.08.005_bib0026","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3324\/haematol.2020.247973","article-title":"Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913","volume":"106","author":"Chiaretti","year":"2021","journal-title":"Haematol"},{"key":"10.1016\/j.clml.2024.08.005_bib0027","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/leu.2017.166","article-title":"Deregulation of kinase signaling and lymphoid development in EBF1-PDGFRB ALL leukemogenesis","volume":"32","author":"Welsh","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.08.005_bib0028","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41375-023-01843-x","article-title":"Unusual PDGFRB fusion reveals novel mechanism of kinase activation in Ph-like B-ALL","volume":"37","author":"Sadras","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.08.005_bib0029","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ebiom.2016.04.038","article-title":"Genomic profiling of adult and pediatric B-cell acute lymphoblastic leukemia","volume":"8","author":"Liu","year":"2016","journal-title":"EBioMed"},{"key":"10.1016\/j.clml.2024.08.005_bib0030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40164-023-00380-8","article-title":"Single-cell heterogeneity and dynamic evolution of Ph-like acute lymphoblastic leukemia patient with novel TPR-PDGFRB fusion gene","volume":"12","author":"Zhang","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.clml.2024.08.005_bib0031","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1182\/blood-2015-09-670166","article-title":"EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications","volume":"127","author":"Schwab","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.005_bib0032","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s12276-020-0484-z","article-title":"The M-CSF receptor in osteoclasts and beyond","volume":"52","author":"Mun","year":"2020","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.clml.2024.08.005_bib0033","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood.2020008536","article-title":"SSBP2-CSF1R is a recurrent fusion in B-lineage acute lymphoblastic leukemia with diverse genetic presentation and variable outcome","volume":"137","author":"Schwab","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.005_bib0034","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1182\/blood.2023021632","article-title":"Acute leukemia with predominantly myeloid differentiation and TBL1XR1::CSF1R fusion","volume":"142","author":"Kumar","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.005_bib0035","doi-asserted-by":"crossref","first-page":"13331","DOI":"10.1038\/ncomms13331","article-title":"Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia","volume":"7","author":"Gu","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2024.08.005_bib0036","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3389\/fonc.2020.00359","article-title":"Rapid molecular response to dasatinib in a pediatric relapsed acute lymphoblastic leukemia with NCOR1-LYN fusion","volume":"10","author":"Dai","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2024.08.005_bib0037","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cancergen.2017.09.001","article-title":"Next-generation sequencing and molecular cytogenetic characterization of ETV6-LYN fusion due to chromosomes 1, 8 and 12 rearrangement in acute myeloid leukemia","volume":"218-219","author":"Ma","year":"2017","journal-title":"Cancer Genet"},{"key":"10.1016\/j.clml.2024.08.005_bib0038","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/leu.2009.167","article-title":"Identification of a novel TEL-Lyn fusion gene in primary myelofibrosis","volume":"24","author":"Tanaka","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.08.005_bib0039","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/S2352-3026(20)30353-7","article-title":"Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study","volume":"8","author":"den Boer","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2024.08.005_bib0040","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1182\/blood.2023023120","article-title":"Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain","volume":"143","author":"van Outersterp","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.005_bib0041","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1182\/blood-2016-12-758250","article-title":"Clonal selection and asymmetric distribution of human leukemia in murine xenografts revealed by cellular barcoding","volume":"129","author":"Belderbos","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.005_bib0042","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3324\/haematol.2010.034173","article-title":"Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis","volume":"96","author":"Soverini","year":"2011","journal-title":"Haematol"},{"key":"10.1016\/j.clml.2024.08.005_bib0043","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1182\/blood-2006-11-052373","article-title":"Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"110","author":"Pfeifer","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.005_bib0044","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.3324\/haematol.2020.261354","article-title":"The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment","volume":"106","author":"Tran","year":"2021","journal-title":"Haematol"},{"key":"10.1016\/j.clml.2024.08.005_bib0045","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood-2017-11-817510","article-title":"PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia","volume":"131","author":"Zhang","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.005_bib0046","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1080\/10428194.2020.1861275","article-title":"In-vitro modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene RANBP2-ABL1 - implications for targeted therapy","volume":"62","author":"Heatley","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2024.08.005_bib0047","doi-asserted-by":"crossref","first-page":"5971","DOI":"10.4049\/jimmunol.163.11.5971","article-title":"Requirement for stat5 in thymic stromal lymphopoietin-mediated signal transduction","volume":"163","author":"Isaksen","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.clml.2024.08.005_bib0048","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1515\/bc.2010.029","article-title":"Signal transduction by the atopy-associated human thymic stromal lymphopoietin (TSLP) receptor depends on Janus kinase function","volume":"391","author":"Wohlmann","year":"2010","journal-title":"Biol Chem"},{"key":"10.1016\/j.clml.2024.08.005_bib0049","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood-2011-12-389932","article-title":"Aberrant STAT5 and PI3K\/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia","volume":"120","author":"Tasian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.005_bib0050","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.coi.2010.10.020","article-title":"The role of thymic stromal lymphopoietin (TSLP) in allergic disorders","volume":"22","author":"Ziegler","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.clml.2024.08.005_bib0051","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.canlet.2014.02.009","article-title":"Towards precision medicine in childhood leukemia\u2013insights from mutationally activated cytokine receptor pathways in acute lymphoblastic leukemia","volume":"352","author":"Izraeli","year":"2014","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clml.2024.08.005_bib0052","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00018-013-1337-x","article-title":"Interleukin 7 and thymic stromal lymphopoietin: from immunity to leukemia","volume":"71","author":"Tal","year":"2014","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.clml.2024.08.005_bib0053","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1182\/blood-2009-08-235408","article-title":"Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group","volume":"115","author":"Hertzberg","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.005_bib0054","doi-asserted-by":"crossref","first-page":"e892","DOI":"10.1097\/HS9.0000000000000892","article-title":"Definition and prognostic value of Ph-like and IKZF1plus status in children with down syndrome and B-cell precursor acute lymphoblastic leukemia","volume":"7","author":"Palmi","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2024.08.005_bib0055","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/ng.469","article-title":"Rearrangement of CRLF2 in B-progenitor- and down syndrome-associated acute lymphoblastic leukemia","volume":"41","author":"Mullighan","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2024.08.005_bib0056","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1182\/blood-2009-03-208397","article-title":"Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia","volume":"114","author":"Russell","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.005_bib0057","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1073\/pnas.0911726107","article-title":"Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia","volume":"107","author":"Yoda","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.clml.2024.08.005_bib0058","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/blood-2009-09-245944","article-title":"Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic\/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia","volume":"115","author":"Harvey","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.005_bib0059","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1038\/s41375-021-01133-4","article-title":"Increased incidence of IKZF1 deletions and IGH-CRLF2 translocations in B-ALL of Hispanic\/Latino children-a novel health disparity","volume":"35","author":"Raca","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.08.005_bib0060","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3324\/haematol.2015.136366","article-title":"Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis","volume":"102","author":"Herold","year":"2017","journal-title":"Haematol"},{"key":"10.1016\/j.clml.2024.08.005_bib0061","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/ng.924","article-title":"Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia","volume":"43","author":"Zenatti","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2024.08.005_bib0062","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1084\/jem.20110580","article-title":"Gain-of-function mutations in interleukin-7 receptor-alpha (IL7R) in childhood acute lymphoblastic leukemias","volume":"208","author":"Shochat","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.clml.2024.08.005_bib0063","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41375-021-01326-x","article-title":"Activated interleukin-7 receptor signaling drives B-cell acute lymphoblastic leukemia in mice","volume":"36","author":"Thomas","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.08.005_bib0064","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.2017.74.3617","article-title":"IKZF1(plus) defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia","volume":"36","author":"Stanulla","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.08.005_bib0065","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/blood.2022019094","article-title":"The genomic landscape of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21","volume":"142","author":"Gao","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.005_bib0066","doi-asserted-by":"crossref","first-page":"5134","DOI":"10.1182\/blood-2012-07-443218","article-title":"Small sizes and indolent evolutionary dynamics challenge the potential role of P2RY8-CRLF2-harboring clones as main relapse-driving force in childhood ALL","volume":"120","author":"Morak","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.005_bib0067","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.18632\/oncotarget.13492","article-title":"Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia","volume":"8","author":"Boer","year":"2017","journal-title":"Oncot"},{"key":"10.1016\/j.clml.2024.08.005_bib0068","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.942053","article-title":"JAK2 alterations in acute lymphoblastic leukemia: molecular insights for superior precision medicine strategies","volume":"10","author":"Downes","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.clml.2024.08.005_bib0069","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1182\/blood-2014-04-570960","article-title":"The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia","volume":"125","author":"Schinnerl","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.005_bib0070","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2021108397","article-title":"The PAX5-JAK2 translocation acts as dual-hit mutation that promotes aggressive B-cell leukemia via nuclear STAT5 activation","volume":"41","author":"Jurado","year":"2022","journal-title":"EMBO J"},{"key":"10.1016\/j.clml.2024.08.005_bib0071","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2310\/JIM.0b013e31820fb28c","article-title":"The erythropoietin receptor: molecular structure and hematopoietic signaling pathways","volume":"59","author":"Watowich","year":"2011","journal-title":"J Investig Med"},{"key":"10.1016\/j.clml.2024.08.005_bib0072","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.3324\/haematol.2021.278697","article-title":"Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"106","author":"Niswander","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2024.08.005_bib0073","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/s41417-021-00421-6","article-title":"Exploring the oncogenic and therapeutic target potential of the MYB-TYK2 fusion gene in B-cell acute lymphoblastic leukemia","volume":"29","author":"Shirazi","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.clml.2024.08.005_bib0074","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1182\/bloodadvances.2019000769","article-title":"Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement","volume":"4","author":"Nardi","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2024.08.005_bib0075","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1182\/blood-2018-05-849554","article-title":"ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition","volume":"132","author":"Roberts","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.005_bib0076","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12111819","article-title":"NTRK gene fusions in solid tumors and TRK inhibitors: a systematic review of case reports and case series","volume":"12","author":"Iannantuono","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.clml.2024.08.005_bib0077","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1182\/bloodadvances.2021004854","article-title":"G3BP2-KIT drives leukemia amenable to kinase inhibition in Ph-like ALL","volume":"6","author":"Iacobucci","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2024.08.005_bib0078","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1002\/hem3.82","article-title":"An integrated classification of tumor suppressor IKZF1 inactivation and oncogenic activation in Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"8","author":"Huang","year":"2024","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2024.08.005_bib0079","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41588-021-00993-x","article-title":"Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation","volume":"54","author":"Yang","year":"2022","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2024.08.005_bib0080","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.2022015853","article-title":"Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia","volume":"140","author":"Duncavage","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.005_bib0081","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/s41375-022-01547-8","article-title":"RNAseqCNV: analysis of large-scale copy number variations from RNA-seq data","volume":"36","author":"Barinka","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.08.005_bib0082","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41588-018-0315-5","article-title":"PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia","volume":"51","author":"Gu","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2024.08.005_bib0083","doi-asserted-by":"crossref","first-page":"e939","DOI":"10.1097\/HS9.0000000000000939","article-title":"The gene expression classifier ALLCatchR identifies B-cell precursor all subtypes and underlying developmental trajectories across age","volume":"7","author":"Beder","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2024.08.005_bib0084","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjh.15251","article-title":"Rapid identification of BCR\/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications","volume":"181","author":"Chiaretti","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2024.08.005_bib0085","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1634\/theoncologist.2018-0272","article-title":"Genomic landscape of adult and pediatric BCR-ABL1-like B-lymphoblastic leukemia using parallel DNA and RNA sequencing","volume":"24","author":"Severson","year":"2019","journal-title":"Oncol"},{"key":"10.1016\/j.clml.2024.08.005_bib0086","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.3324\/haematol.2019.231720","article-title":"Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols","volume":"105","author":"Cario","year":"2020","journal-title":"Haematol"},{"key":"10.1016\/j.clml.2024.08.005_bib0087","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1182\/blood.2019001244","article-title":"Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements","volume":"134","author":"Tanasi","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.005_bib0088","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjh.17093","article-title":"Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion","volume":"191","author":"Moorman","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2024.08.005_bib0089","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/leu.2014.30","article-title":"Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: children's oncology group study AALL0031","volume":"28","author":"Schultz","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.08.005_bib0090","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1200\/JCO.2017.76.7228","article-title":"Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of children's oncology group trial AALL0622","volume":"36","author":"Slayton","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.08.005_bib0091","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1470-2045(12)70377-7","article-title":"Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study","volume":"13","author":"Biondi","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.08.005_bib0092","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S2352-3026(23)00088-1","article-title":"Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372\/COG AALL1122): a single-arm, multicentre, phase 2 trial","volume":"10","author":"Hunger","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2024.08.005_bib0093","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-Cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2024.08.005_bib0094","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/jama.2021.8154","article-title":"Blinatumomab vs chemotherapy among children with relapsed acute lymphoblastic leukemia-reply","volume":"326","author":"Locatelli","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2024.08.005_bib0095","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.08.005_bib0096","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.08.005_bib0097","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1001\/jama.2024.4783","article-title":"Ponatinib vs imatinib in frontline Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial","volume":"331","author":"Jabbour","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2024.08.005_bib0098","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1182\/blood-2012-04-422691","article-title":"Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the children's oncology group TARGET project","volume":"121","author":"Loh","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.005_bib0099","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1182\/blood-2010-07-297135","article-title":"Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial","volume":"117","author":"Ensor","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.005_bib0100","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2011.40.3907","article-title":"IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia","volume":"30","author":"Moorman","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.08.005_bib0101","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1182\/blood-2012-10-462358","article-title":"Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL","volume":"122","author":"van der Veer","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.005_bib0102","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/pbc.25575","article-title":"A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: a children's oncology group phase 1 consortium study (ADVL1011)","volume":"62","author":"Loh","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2024.08.005_bib0103","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.3324\/haematol.2018.192088","article-title":"Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure","volume":"103","author":"Ding","year":"2018","journal-title":"Haematol"},{"key":"10.1016\/j.clml.2024.08.005_bib0104","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26328","article-title":"Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemia","volume":"64","author":"Mayfield","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2024.08.005_bib0105","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2014.55.4105","article-title":"Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease","volume":"32","author":"Roberts","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.08.005_bib0106","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1080\/10428194.2019.1605510","article-title":"Response to single agent dasatinib post allogeneic transplant in B-cell acute lymphoblastic leukemia with NUP214-ABL1","volume":"60","author":"Aldoss","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2024.08.005_bib0107","doi-asserted-by":"crossref","first-page":"e1901","DOI":"10.1002\/cnr2.1901","article-title":"Pre- and post-HSCT use of TKI therapy for fusion-driven B-ALL: a case series of five pediatric, adolescent and young adult patients","volume":"6","author":"Shumock","year":"2023","journal-title":"Cancer Rep (Hoboken)"},{"key":"10.1016\/j.clml.2024.08.005_bib0108","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13045-023-01409-5","article-title":"The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades","volume":"16","author":"Jabbour","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2024.08.005_bib0109","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood.2020010144","article-title":"Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL","volume":"138","author":"Paietta","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.005_bib0110","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.005_bib0111","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccell.2015.06.005","article-title":"Activity of the type II JAK2 inhibitor CHZ868 in B cell acute lymphoblastic leukemia","volume":"28","author":"Wu","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2024.08.005_bib0112","article-title":"Philadelphia-like genetic rearrangements in adults with B-Cell ALL: refractoriness to chemotherapy and response to tyrosine kinase inhibitor in ABL class rearrangements","volume":"7","author":"Senapati","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.clml.2024.08.005_bib0113","doi-asserted-by":"crossref","first-page":"E379","DOI":"10.1002\/ajh.26281","article-title":"Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed\/refractory acute lymphoblastic leukemia: a post hoc analysis from the phase 3 tower study","volume":"96","author":"Jabbour","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2024.08.005_bib0114","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1182\/blood.2020006287","article-title":"Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL","volume":"137","author":"Zhao","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.005_bib0115","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/ajh.26908","article-title":"High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed\/refractory acute lymphoblastic leukemia with Philadelphia-like fusions","volume":"98","author":"Aldoss","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2024.08.005_bib0116","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021012727","article-title":"Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy","volume":"139","author":"Leahy","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.005_bib0117","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41408-021-00538-9","article-title":"Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH-based algorithm distinguishes prognostic groups and outcomes","volume":"11","author":"Abdel-Rahman","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2024.08.005_bib0118","doi-asserted-by":"crossref","first-page":"4936","DOI":"10.1182\/bloodadvances.2022007597","article-title":"Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL","volume":"6","author":"Aldoss","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2024.08.005_bib0119","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1038\/s41409-021-01253-6","article-title":"Non-inferior long-term outcomes of adults with Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"56","author":"Cho","year":"2021","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.clml.2024.08.005_bib0120","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1182\/asheducation-2016.1.561","article-title":"Ph-like acute lymphoblastic leukemia","volume":"2016","author":"Tran","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2024.08.005_bib0121","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1038\/s41375-023-02010-y","article-title":"Preclinical development of 1B7\/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL","volume":"37","author":"Tian","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.08.005_bib0122","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/ejh.13948","article-title":"Clinical, biological, and outcome features of P2RY8-CRLF2 and CRLF2 over-expression in pediatric B-cell precursor acute lymphoblastic leukemia according to the CCLG-ALL 2008 and 2018 protocol","volume":"110","author":"Wang","year":"2023","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2024.08.005_bib0123","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/ajh.27227","article-title":"Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am J Hematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T06:39:23Z","timestamp":1736059163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024002969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":123,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2152265024002969"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.08.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Approach to BCR::ABL1-Like Acute Lymphoblastic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}